Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AKTX

Akari Therapeutics Plc ADR

May 22 • 04:00PM ET

18.27

+13.13 255.45 %

Healthcare • Biotechnology • USA • Nano • NASD

May 22, 5:30 PMDilutive $5.5M private placement sparks 25% after-hours reversal in AKTX after data-fueled surge

Peers: MREO LRMR OCGN BDTX VNDA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-18.86	Insider Own	0.40%	Shs Outstand	1.14M	Perf Week	423.50%
Market Cap	20.83M	Forward P/E	-	EPS next Y	-4.68	Insider Trans	0.00%	Shs Float	1.14M	Perf Month	204.50%
Enterprise Value	18.73M	PEG	-	EPS next Q	-1.33	Inst Own	5.91%	Short Float	1.42%	Perf Quarter	87.96%
Income	-28.00M	P/S	-	EPS this Y	72.10%	Inst Trans	-39.16%	Short Ratio	0.12	Perf Half Y	-8.41%
Sales	0.00M	P/B	1.45	EPS next Y	18.89%	ROA	-66.00%	Short Interest	0.02M	Perf YTD	58.04%
Book/sh	12.56	P/C	7.36	EPS next 5Y	32.82%	ROE	-155.01%	52W High	56.80 -67.83%	Perf Year	-63.60%
Cash/sh	2.48	P/FCF	-	EPS past 3/5Y	- -	ROIC	-194.71%	52W Low	3.02 505.97%	Perf 3Y	-88.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	45.58% 23.80%	Perf 5Y	-98.76%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.85%	Oper. Margin	-	ATR (14)	1.76	Perf 10Y	-99.84%
Dividend Ex-Date	-	Quick Ratio	0.27	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	84.22	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.27	EPS Q/Q	-75.83%	SMA20	231.22%	Beta	0.65	Target Price	33.50
Payout	-	Debt/Eq	0.05	Sales Q/Q	-	SMA50	234.49%	Rel Volume	250.20	Prev Close	5.14
Employees	6	LT Debt/Eq	0.00	Earnings	Apr 07	SMA200	1.62%	Avg Volume	133.54K	Price	18.27
IPO	May 07, 2013	Option/Short	No / No	EPS/Sales Surpr.	-66.11% -	Trades		Volume	33,411,338	Change	255.45%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Downgrade	Maxim Group	Buy → Hold
Jan-05-26	Initiated	Ladenburg Thalmann	Buy	$1
Jul-18-25	Initiated	Maxim Group	Buy	$5
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

May-21-26 05:01PM	Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models (GlobeNewswire) +49.85% +255.45%
08:30AM	Akari Therapeutics Announces $5.5 Million Private Placement Offering (GlobeNewswire)
May-18-26 09:05AM	Akari Therapeutics to Present at A.G.P.'s Annual Healthcare Company Showcase (GlobeNewswire)
May-12-26 08:33AM	Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets (GlobeNewswire) -40.58%
Apr-27-26 08:35AM	Akari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC Payload (GlobeNewswire)
09:00AM	Loading…
Apr-21-26 09:00AM	Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors (GlobeNewswire)
Apr-20-26 08:35AM	Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing (GlobeNewswire)
Apr-09-26 08:50AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC (GlobeNewswire)
Apr-06-26 08:45AM	Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing (GlobeNewswire) -20.81%
Mar-18-26 08:05AM	Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026 (GlobeNewswire) -24.72%
Mar-17-26 04:30PM	Akari Therapeutics Announces ADS Ratio Change (GlobeNewswire)
Mar-13-26 09:15AM	Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala (GlobeNewswire) -10.71%
Feb-26-26 09:10AM	Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board (GlobeNewswire)
Feb-23-26 08:50AM	Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board (GlobeNewswire)
Feb-18-26 09:05AM	Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference (GlobeNewswire)
08:45AM	Loading…
Feb-11-26 08:45AM	Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline (GlobeNewswire)
Feb-05-26 09:15AM	Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire)
Jan-26-26 08:45AM	Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors (GlobeNewswire)
Jan-17-26 07:00AM	MarketBeat Week in Review - 01/12 - 01/16 (MarketBeat)
Jan-09-26 09:00AM	Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 (GlobeNewswire)
Jan-08-26 09:15AM	Akari Therapeutics to Present at the 2026 Biotech Showcase (GlobeNewswire)
Dec-30-25 09:15AM	Akari Therapeutics Issues 2025 End of Year Letter to Shareholders (GlobeNewswire)
Dec-23-25 08:30AM	Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial (GlobeNewswire) -7.08%
Dec-18-25 08:30AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Dec-16-25 09:29AM	Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market (GlobeNewswire) -38.30%
Dec-09-25 08:40AM	Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer (GlobeNewswire)
Dec-04-25 09:00AM	Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment (GlobeNewswire)
Nov-25-25 09:00AM	Akari Therapeutics Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Nov-18-25 08:35AM	Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer (GlobeNewswire) +12.04%
Nov-10-25 08:30AM	Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors (GlobeNewswire)
09:25AM	Loading…
Nov-04-25 09:25AM	Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available (GlobeNewswire) +13.10%
Oct-30-25 08:35AM	Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP (GlobeNewswire)
Oct-22-25 09:05AM	Akari Therapeutics Announces Launch of CEO Corner Platform (GlobeNewswire)
Oct-15-25 08:30AM	Akari Therapeutics Announces $2.5 Million Registered Direct Offering (GlobeNewswire) -16.34%
Oct-10-25 08:50AM	Akari Therapeutics files two new patents with USPTO (TipRanks) -8.82%
Oct-09-25 08:45AM	Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1 (GlobeNewswire)
Oct-03-25 09:30AM	Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire)
Sep-24-25 08:45AM	Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1 (GlobeNewswire) +45.96%
Sep-17-25 08:45AM	Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer (GlobeNewswire) +5.11%
Sep-05-25 06:45AM	Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +12.15%
Sep-03-25 08:30AM	Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) -6.42%
Aug-14-25 09:15AM	Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Jul-29-25 09:15AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment (GlobeNewswire)
Jul-23-25 08:55AM	Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers (GlobeNewswire)
Jul-22-25 08:45AM	Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jun-25-25 09:00AM	Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent (GlobeNewswire)
Jun-18-25 08:50AM	Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India (GlobeNewswire)
May-29-25 09:15AM	Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology (GlobeNewswire)
May-22-25 09:00AM	Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
May-19-25 08:00AM	Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair (GlobeNewswire)
May-15-25 08:05AM	Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-01-25 08:45AM	Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology (GlobeNewswire)
Apr-22-25 09:05AM	Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala (GlobeNewswire) +6.25%
Apr-16-25 08:00AM	Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -8.24%
Mar-20-25 08:44AM	Akari Therapeutics appoints Abizer Gaslightwala as CEO (SeekingAlpha) +20.00%
08:35AM	Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer (GlobeNewswire)
Mar-03-25 09:00AM	Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules (GlobeNewswire) +7.70%
Feb-19-25 09:00AM	Akari Therapeutics Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire) +5.30%
Feb-03-25 08:00AM	Akari Therapeutics Joins Webull Corporate Connect Service Platform (GlobeNewswire) +9.17%
Dec-18-24 08:51AM	Akari Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
Dec-16-24 09:05AM	Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer (GlobeNewswire)
Nov-19-24 08:00AM	Akari Therapeutics Regains Full Nasdaq Compliance (GlobeNewswire) -31.44%
Nov-14-24 04:15PM	Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio (GlobeNewswire) -6.73%
Nov-08-24 08:00AM	Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger (GlobeNewswire)
Oct-15-24 08:00AM	Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger (GlobeNewswire)
Sep-17-24 08:00AM	Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics (GlobeNewswire)
Aug-19-24 04:15PM	Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire) +5.42%
08:00AM	Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy (GlobeNewswire)
Jun-05-24 08:00AM	Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders (GlobeNewswire) +9.88%
Jun-04-24 08:00AM	Akari Therapeutics Secures $7.6 Million in Upsized Financing Round (GlobeNewswire) +14.20%
May-16-24 08:00AM	Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
May-01-24 08:01AM	Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM	Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

CEOMr. Abizer Gaslightwala

Interim Chief Financial OfficerMr. Kameel D. Farag

Executive Director & Head of OncologyDr. Satyajit Mitra Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gaslightwala Abizer	CEO	Aug 21 '25	Buy	0.94	10,000	9,400	287,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 22 '25	Buy	0.93	8,000	7,440	295,574	Aug 29 04:55 PM
Gaslightwala Abizer	CEO	Aug 25 '25	Buy	0.90	3,000	2,700	298,574	Aug 29 04:55 PM
Gaslightwala Abizer	President & CEO	Jun 24 '25	Buy	1.16	5,203	6,035	277,574	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 23 '25	Buy	1.15	943	1,084	272,371	Jun 25 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 20 '25	Buy	1.20	10,000	12,000	271,428	Jun 24 04:30 PM
Gaslightwala Abizer	President & CEO	Jun 17 '25	Buy	1.20	15,000	18,000	261,428	Jun 20 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your Finviz experience